Original site: www.cdc.gov/mmwr/preview/mmwrhtml/00021198.htm RestoredCDC.org is an independent project and is not affiliated with, endorsed by, or associated with the Centers for Disease Control and Prevention (CDC) or any government entity. The CDC provides information free of change at CDC.gov. Note the following: 1) Due to archival on January 6, 2025, no information on recent outbreaks is available. 2) Videos have not been restored. 3) Use of this site implies acceptance of this disclaimer.
In the MMWR Recommendations and Reports, "Initial Therapy for
Tuberculosis in the Era of Multidrug Resistance, Recommendations of
the Advisory Council for the Elimination of Tuberculosis," dated
May 21, 1993, on page 3, Option 1 in Table 1 should read as
follows: Administer daily INH, RIF, and PZA for 8 weeks followed by
16 weeks of INH and RIF daily or 2-3 times/week *. In areas where
the INH resistance rate is not documented to be less than 4%, EMB
or SM should be added to the initial regimen until susceptibility
to INH and RIF is demonstrated. Continue treatment for at least 6
months and 3 months beyond culture conversion. Consult a TB medical
expert if the patient is symptomatic or smear or culture positive
after 3 months.
In addition, add the following citation to the reference
section:
17. CDC. National action plan to combat multidrug-resistant
tuberculosis. MMWR 1992;41(no. RR-11):1-30.
Disclaimer
All MMWR HTML versions of articles are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the electronic PDF version and/or the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.
